Document is current
Any future updates will be listed below
-
Authors
Fennell, Dean A. https://orcid.org/0000-0001-7373-1312
Sekido, Yoshitaka https://orcid.org/0000-0002-2428-3848
Baas, Paul https://orcid.org/0000-0001-7018-9556
Husain, Aliya N.
Curioni-Fontecedro, Alessandra https://orcid.org/0000-0002-5778-5270
Lim, Eric
Opitz, Isabelle https://orcid.org/0000-0001-5900-9040
Simone, Charles B. II https://orcid.org/0000-0002-0867-3694
Brims, Fraser https://orcid.org/0000-0002-6725-7535
Wong, Martin Chi-sang https://orcid.org/0000-0001-7706-9370
- License Information
-
More Information
Article History
Accepted: 14 July 2025
First Online: 7 August 2025
Competing interests
: D.A.F.: grants from Aldeyra, Astex Therapeutics, Bayer, BMS, Boehringer Ingelheim, Owkin; non-financial support from BerGenBio, Clovis, Eli Lilly, MSD, Roche and Tesaro GSK; personal fees from Aldeyra, Cambridge Clinical Laboratories, Ikena, Opna Bio, Owkin, RS Oncology, Roche, MSD, during the conduct of the study; I.O.: Roche (institutional grant), AstraZeneca (advisory board), MSD (advisory board), BMS (advisory board), Medtronic (institutional grant and advisory board), Intuitive (proctorship and speaker’s fee), Sanofi (speaker’s fee), Regeneron (advisory board), XVIVO (institutional grant), Siemens (speaker’s fee), Astellas (speaker’s fee). I.O. is the International Director for AATS, a member of the Thoracic Clinical Practice Standards Committee and the Thoracic Education Committee of AATS, an ESTS board member, an iMig board member and The Journal of Thoracic and Cardiovascular Surgery Associate Editor. The other authors declare no competing interests.
